All In Biotech

Free tool

FAERS Monitor: Baxdela

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208611 or its brand name (Baxdela, Delafloxacin Meglumine). Reports on generic versions are filed under their own applications.

Reports

242

Serious

67

28% of reports

Hospitalization

21

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea76
  • off label use28
  • nausea19
  • decreased appetite14
  • rash13
  • malaise12
  • arthralgia10
  • drug effective for unapproved indication10
  • product use in unapproved indication10
  • tremor10
  • hypertension9
  • pallor9
  • presyncope9
  • autonomic nervous system imbalance8
  • drug ineffective7

Reports by year received

View as table
YearReports
201864
2019110
202031
20216
20228
20233
20244
202513
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,917 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
autonomic nervous system imbalanceSignal8238.7120.61,659
presyncopeSignal932.216.9242
drug effective for unapproved indicationSignal1029.716.2249
pallorSignal928.815.1214
diarrhoeaSignal7610.28.5644
decreased appetiteSignal145.23.244
tremorSignal105.22.930
hypertensionSignal93.71.915
product use in unapproved indicationSignal103.51.916
off label useSignal282.82.031
rashSignal132.61.511
malaiseSignal122.41.48
arthralgiaSignal102.11.15
nauseaSignal192.11.410
drug ineffective70.50.24

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.